Dueling for Defibrillators
Updated from 1:34 p.m. EST
The cash and stock offer from Boston Scientific is worth $25 billion, or $72 a share. That's about $3 billion more than a recently revised offer by J&J for Indianapolis-based Guidant.
However, it's also about $4 a share less than the original cash and stock offer that J&J made last year. A series of recalls of Guidant products following the first bid prompted J&J to reduce its offer on Nov. 15. The revised J&J deal was worth $63.08 at the middle of last month and was valued at $63.43 as of Friday.The boards of Guidant and J&J approved the revised offer, which still must be endorsed by the companies' shareholders. Guidant acknowledged receipt of the Boston Scientific bid, saying its board would consider it. J&J, based in New Brunswick, N.J., had no immediate comment. The announcement by Boston Scientific -- whose market capitalization of $22.5 billion is about one-eighth the size of J&J's and about the same as Guidant's -- touched off furious trading among the three players. Shares of Boston Scientific were erratic, falling as low as $25.51 and climbing as high as $27.73. The stock closed at $26.35, down 98 cents, or 3.6% on the day. Roughly 38 million shares traded, or more than eight times the average daily volume for the past three months. Guidant jumped $6.16, or 10%, to $67.98, after going as high as $68.20, while J&J lost 16 cents to $61.05. Volume in both was heavy. "We are surprised by this latest turn of events," says Joann Wuensch of Harris Nesbitt in a research note to clients. She retained her neutral rating on Boston Scientific. "Given Boston Scientific's market capitalization ... this appears to be a big nut to crack." She doesn't own shares, and her firm doesn't have an investment banking relationship.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV